Cervical Cancer Clinical Trial
Official title:
Development of a Two-stage Cervical Cancer Screening Algorithm for Botswana
Cervical cancer is the leading cause of cancer death among women in Botswana. The burden of cervical cancer is largely related to the high prevalence of HIV in Botswana (22%), as HIV is known to be a significant risk factor for cervical cancer. Cervical cancer screening is life-saving and has been shown to reduce cervical cancer incidence in multiple settings. Yet, there is no consensus on appropriate screening algorithms for women living with HIV, across resource settings. Botswana is in a unique position, relative to its neighbors in Sub-Saharan Africa, in that there exists capacity for advanced screening modalities, including primary high risk human papilloma virus (hrHPV) testing and cytology-based screening. To address this issue, this study seeks to evaluate two-stage cervical cancer screening algorithms for women living with HIV in Botswana using hrHPV testing. The protocols include hrHPV testing followed by Pap Smear evaluation, VIA and colposcopy. These same participants will be invited back at one-year for cervical cancer screening using hrHPV testing (followed by triage testing) in order to inform guidelines on the frequency of HPV testing in women living with HIV. The evidence generated will be critical to guiding cervical cancer screening in HIV-infected women across resource settings.
Cervical cancer screening programs vary across settings and there is no clear guidance for
effective screening programs for HIV-positive women. Evaluating the performance of algorithms
that include human papillomavirus (HPV) DNA testing as first stage screening in high HIV
prevalence settings like Botswana is essential for establishing an evidence-based strategy
for cervical cancer screening in HIV-positive women.
This study seeks to evaluate the performance of two-stage cervical cancer screening
algorithms using primary HPV testing in women living with HIV in Botswana. Second stage
screening modalities include Papanicolaou (Pap) smear, visual inspection with acetic acid
(VIA) and colposcopy.
The study will enroll 300 HIV positive women. For all 300 participants, gynecologic speculum
exam will be performed and provider-collected cervical swabs will be collected for HPV
testing and Pap smear preparation. HPV testing will be performed with either the
commercially-available Cepheid Xpert® HPV Assay or a high throughput PCR platform. Pap smear
will be prepared using standard technique at the site of collection.
Participants who test HPV-negative will have their Pap smear sent to the National Health Lab
(NHL) for staining and pathologist evaluation. If the Pap smear is abnormal, they will be
referred to colposcopy per current Botswana Cervical Cancer Prevention Guidelines.
Participants who test HPV-positive will also have their Pap smear reviewed, and will also be
asked to return for colposcopy and will undergo further diagnosis and treatment for cervical
cancer per national guidelines. At the colposcopy visit, a trained nurse will conduct VIA
using the Botswana standard protocol. After application of acetic acid to the cervix, the
nurse will record visual results as positive or negative. If VIA is positive based on
assessment of the lesion(s), the nurse will record a recommendation for either cryotherapy or
loop electrosurgical excision procedure (LEEP). Since all of these HPV-positive participants
will undergo colposcopy, the participants will not be informed of the VIA results, as neither
cryotherapy nor LEEP will be administered based on the VIA results. Rather, the participants
will proceed to colposcopy and results of colposcopy will determine further diagnosis and
treatment. This design enables us to assess the utility of the two-stage algorithms while
providing the highest-quality follow-up to cervical cancer screening abnormalities in
Botswana.
These same participants will be invited back at one-year for repeat cervical cancer screening
using the same screening methods as at baseline. The data will inform guidelines on the
frequency of hrHPV testing in women living with HIV.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06223308 -
A Study Evaluating the Safety and Efficacy of HB0028 in Subjects With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Terminated |
NCT03367871 -
Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Cervical Cancer
|
Phase 2 | |
Active, not recruiting |
NCT04537156 -
Efficacy, Immunogenicity and Safty Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli)
|
Phase 3 | |
Recruiting |
NCT03668639 -
Safety and Antiemetic Efficacy of Akynzeo Plus Dexamethasone During Radiotherapy and Concomitant Weekly Cisplatin
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT04242199 -
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
|
Phase 1 | |
Withdrawn |
NCT04806945 -
A Phase III Study to Evaluate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy in Patients With Advanced Cervical Cancer
|
Phase 3 | |
Active, not recruiting |
NCT04185389 -
Long-Term Follow-Up of HPV FOCAL Participants
|
||
Withdrawn |
NCT03007771 -
Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia
|
Phase 1 | |
Completed |
NCT03384511 -
The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.
|
Phase 4 | |
Recruiting |
NCT05107674 -
A Study of NX-1607 in Adults With Advanced Malignancies
|
Phase 1 | |
Completed |
NCT05120167 -
Strategies for Endocervical Canal Investigation in Women With Abnormal Screening Cytology and Negative Colposcopy
|
N/A | |
Recruiting |
NCT05483491 -
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
|
Phase 1 | |
Recruiting |
NCT05736588 -
Elimisha HPV (Human Papillomavirus)
|
N/A | |
Completed |
NCT05862844 -
Promise Women Project
|
N/A | |
Recruiting |
NCT04934982 -
Laparoscopic or Abdominal Radical Hysterectomy for Cervical Cancer(Stage IA1 With LVSI, IA2)
|
N/A | |
Recruiting |
NCT03876860 -
An Enhanced Vaginal Dilator to Reduce Radiation-Induced Vaginal Stenosis
|
N/A | |
Completed |
NCT03652077 -
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
|
Phase 1 | |
Completed |
NCT00543543 -
Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001)
|
Phase 3 | |
Terminated |
NCT04864782 -
QL1604 Plus Chemotherapy in Subjects With Stage IVB, Recurrent, or Metastatic Cervical Cancer
|
Phase 2/Phase 3 | |
Recruiting |
NCT04226313 -
Self-sampling for Non-attenders to Cervical Cancer Screening
|
N/A |